Iclusig 15 mg compresse rivestite con film Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

iclusig 15 mg compresse rivestite con film

incyte biosciences international sàrl - ponatinibum - compresse rivestite con film - ponatinibum 15 mg per ponatinibi hydrochloridum, excipiens pro compresso haze. - agente antineoplastico - synthetika

Iclusig 45 mg compresse rivestite con film Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

iclusig 45 mg compresse rivestite con film

incyte biosciences international sàrl - ponatinibum - compresse rivestite con film - ponatinibum 45 mg per ponatinibi hydrochloridum, excipiens pro compresso haze. - agente antineoplastico - synthetika

Iclusig 30 mg compresse rivestite con film Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

iclusig 30 mg compresse rivestite con film

incyte biosciences international sàrl - ponatinibum - compresse rivestite con film - ponatinibum 30 mg a ponatinibi hydrochloridum, excipiens pro compresso haze. - agente antineoplastico - synthetika

Pemazyre 4,5 mg compresse Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

pemazyre 4,5 mg compresse

incyte biosciences international sàrl - pemigatinibum - compresse - pemigatinibum 4.5 mg, cellulosum microcristallinum, carboxymethylamylum natricum a corresp. natrium 0.176 mg, magnesii stearas, pro compresso. - cholangiocarcinome - synthetika

Pemazyre 9 mg compresse Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

pemazyre 9 mg compresse

incyte biosciences international sàrl - pemigatinibum - compresse - pemigatinibum 9 mg, cellulosum microcristallinum, carboxymethylamylum natricum a corresp. natrium 0.352 mg, magnesii stearas, pro compresso. - cholangiocarcinome - synthetika

Pemazyre 13,5 mg compresse Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

pemazyre 13,5 mg compresse

incyte biosciences international sàrl - pemigatinibum - compresse - pemigatinibum 13.5 mg, cellulosum microcristallinum, carboxymethylamylum natricum a corresp. natrium 0.528 mg, magnesii stearas, pro compresso. - cholangiocarcinome - synthetika

Minjuvi 200 mg polvere per soluzione per infusione Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

minjuvi 200 mg polvere per soluzione per infusione

incyte biosciences international sàrl - tafasitamabum - polvere per soluzione per infusione - praeparatio cryodesiccata: tafasitamabum 200 mg, natrii citras dihydricus corresp. natrium 7.4 mg, acidum citricum monohydricum, trehalosum dihydricum, polysorbatum 20, pro vitro. - lymphome diffus à grandes cellules b (dlbcl) - biotechnologika

Iclusig Unione Europea - italiano - EMA (European Medicines Agency)

iclusig

incyte biosciences distribution b.v. - ponatinib - leukemia, myeloid; leukemia, lymphoid - antineoplastic agents, protein kinase inhibitors - iclusig is indicated in adult patients withchronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutationphiladelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation. vedi sezioni 4. 2 assessment of cardiovascular status prior to start of therapy and 4. 4 situations where an alternative treatment may be considered.

Pemazyre Unione Europea - italiano - EMA (European Medicines Agency)

pemazyre

incyte biosciences distribution b.v. - pemigatinib - cholangiocarcinoma - agenti antineoplastici - pemazyre monotherapy is indicated for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed  after at least one prior line of systemic therapy.

Minjuvi Unione Europea - italiano - EMA (European Medicines Agency)

minjuvi

incyte biosciences distribution b.v. - tafasitamab - lymphoma, large b-cell, diffuse - agenti antineoplastici - minjuvi is indicated in combination with lenalidomide followed by minjuvi monotherapy for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) who are not eligible for autologous stem cell transplant (asct).